Nirma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nirma Limited, the promoter of Alivus Life Sciences Limited (formerly Glenmark Life Sciences), has filed a regulatory disclosure with the stock exchanges stating that it has not created any encumbrance (such as a pledge or lien) on its shares of Alivus during the financial year 2024-25. This is a mandatory annual filing under SEBI's Substantial Acquisition of Shares and Takeovers Regulations. The disclosure confirms that the promoter's entire shareholding in Alivus remains free of any pledges or encumbrances.
This is a routine compliance filing and is neutral to mildly positive for shareholders, as it confirms the promoter's stake is fully unencumbered, reducing concerns over potential forced share sales due to pledge-related risks.